<?xml version="1.0" encoding="UTF-8"?>
<ref id="B44">
 <label>44</label>
 <mixed-citation publication-type="other">
  <person-group person-group-type="author">
   <name>
    <surname>Lonez</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Verma</surname>
    <given-names>B</given-names>
   </name>
   <name>
    <surname>Hendlisz</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Aftimos</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Awada</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Van Den Neste</surname>
    <given-names>E</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Study protocol for THINK: A multinational open-label phase i study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types</article-title>. 
  <source>BMJ Open</source> (
  <year>2017</year>). Â 
  <pub-id pub-id-type="doi">10.1136/bmjopen-2017-017075</pub-id>
 </mixed-citation>
</ref>
